Key result
CGM time-in-range moderately predicts 10-year ASCVD risk in adults without diabetes with ~0.75 AUC.
Why the study?
Are continuous glucose monitor derived time in range and glycaemic variability associated with diet, lifestyle, and cardiometabolic risk markers in individuals without diabetes?
Observational (n=3,634)
Are continuous glucose monitor derived time in range and glycaemic variability associated with diet, lifestyle, and cardiometabolic risk markers in individuals without diabetes?
Effect estimate: AUC 0.75
Continuous glucose monitoring metrics capture components of glycaemic physiology and correlate with predicted ASCVD risk in euglycaemic individuals, though long-term clinical utility remains to be established.
Continuous glucose monitors (CGMs) provide detailed glucose profiles, but their relevance to health outcomes in individuals without diabetes remains unclear. Here we assess time in range (TIR3.9–5.6 and TITR3.9-7.8) and glycaemic variability in individuals (N = 3,634; age 46 ± 12 y; 83% female; BMI 27 ± 6 kg/m²) from PREDICT 1 (NCT03479866), PREDICT 2 (NCT03983733), and PREDICT 3 (NCT04735835) without diabetes or prediabetes, and explore associations with demographic, diet, lifestyle, cardiometabolic markers, and predicted cardiovascular risk. Outcomes are non-pre-defined exploratory analyses. Higher TIR3.9–5.6 is associated with lower HbA1c, OGTT glucose, carbohydrate intake, and higher protein intake. Sleep duration is inversely correlated with mean glucose. TIR3.9–5.6 provided moderate discrimination for predicted ASCVD 10-year risk (AUC = 0.75). While CGM metrics show potential to capture some components of glycaemic physiology, longer-term health outcomes are required to demonstrate whether CGM monitoring has utility for health management in euglycaemic individuals. Here, the authors show that continuous glucose metrics capture some components of glycaemic physiology in euglycaemic individuals. An evaluation of health outcomes longer-term would be required to assess whether continuous glucose monitoring has utility for health management in this population.
No takes yet. Share an insight, caveat, or question.
Bermingham et al. (2026) conducted an observational in Euglycaemia (without diabetes or prediabetes) (n=3,634). Continuous glucose monitor derived time in range and glycaemic variability was evaluated on Predicted ASCVD 10-year risk (AUC 0.75). In individuals without diabetes or prediabetes, continuous glucose monitor derived time in range (TIR3.9-5.6) provided moderate discrimination for predicted ASCVD 10-year risk (AUC = 0.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: